Recs

0

I'd Take IBM's Problems

It's the same story from IBM (NYSE: IBM  ) , but it never really gets old.

In the face of a possible American recession, Big Blue delivered 28% earnings growth on 13% higher revenue, based on balanced performance across the globe in various product categories, with a healthy mix of supporting services. $26.8 billion in sales is nothing to sneeze at, nor is $1.98 of earnings per share for an earnings yield of 6.3% at the current run rate. Good luck finding a savings account with that kind of return on your invested capital.

Oracle (Nasdaq: ORCL  ) would be very satisfied with a 28% year-over-year earnings improvement, and Larry Ellison is probably gritting his teeth right now at his biggest rival's success. The same goes for German enterprise software competitor SAP AG (NYSE: SAP  ) or even domestic nemesis Microsoft (Nasdaq: MSFT  ) -- any of these guys would take IBM's numbers over their own at the moment.

And it looks like the success story will continue. "We entered the second quarter with a strong deal pipeline and this quarter, frankly, we were sold out," said CFO Mark Loughridge. Large contracts with pharma giant Pfizer (NYSE: PFE  ) and office equipment biggie Ricoh (OTC BB: RICOY) helped Big Blue saturate its order capacity, and the next quarter should be just as impressive as this one.

One of the biggest tech businesses in the world has completely filled its order book? Now that’s a nice problem to have. Keep looking for trouble, IBM.

Further Foolishness:

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

Pfizer is a Motley Fool Income Investor selection. Pfizer and Microsoft are Motley Fool Inside Value recommendations. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Anders Bylund holds no position in any of the companies discussed here. You can check out Anders' holdings if you like, and Foolish disclosure is always looking for the right kind of trouble.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 688255, ~/Articles/ArticleHandler.aspx, 2/14/2012 2:53:09 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 12,874.04 72.81 0.57%
S&P 500 1,351.77 9.13 0.68%
NASD 2,931.39 27.51 0.95%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/13/2012 4:01 PM
IBM $192.62 Up +0.20 +0.10%
International Busi… CAPS Rating: ****
PFE $21.30 Up +0.25 +1.19%
Pfizer, Inc. CAPS Rating: ****
SAP $63.33 Up +0.43 +0.68%
SAP AG (ADR) CAPS Rating: ***
MSFT $30.58 Up +0.09 +0.28%
Microsoft Corp CAPS Rating: ***
ORCL $28.43 Down -0.07 -0.23%
Oracle Corp. CAPS Rating: ****

Advertisement